Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The phrase "Streptococcus pneumoniae type 9V capsular polysaccharide antigen-specific B cells" does not refer to a single molecular target, but rather to a population of **B cells**—a type of immune cell—that recognize the capsular polysaccharide antigen of **Streptococcus pneumoniae serotype 9V**. These B cells produce antibodies specific for the type 9V capsular polysaccharide, which is a component of several pneumococcal vaccines and is used in studying immunogenicity and vaccine response. While the **capsular polysaccharide antigen** itself is a therapeutic target as a vaccine antigen, **antigen-specific B cells** are not themselves drug targets or recognized molecular entities, but rather functional lymphocyte subsets identified by their specificity for this antigen[3][6]. --- **Explanation and Justification:** - The query mixes the concept of a **molecule/antigen** (type 9V capsular polysaccharide) with a **cell population** (antigen-specific B cells). - **Streptococcus pneumoniae type 9V capsular polysaccharide antigen** is the actual vaccine antigen and can be considered a therapeutic target as a component of pneumococcal vaccines[3][6]. - **[Antigen]-specific B cells**, however, are not molecular targets but immune cells that recognize and respond to this antigen. - This means the query is **incorrect** for the purpose of molecular target curation—it does not describe a receptor, enzyme, transporter, or defined protein/nucleic acid, but rather an immune cell population defined by antigen specificity. - Therefore, most requested fields do not apply or should be null. For structured data, the correct approach is to reject this as a canonical molecular target and, if relevant, curate the *actual antigen* (the capsular polysaccharide) instead[3][6]. If you intend to curate the molecular target, the correct entry would be for the **Streptococcus pneumoniae type 9V capsular polysaccharide antigen** (see DrugBank[6], PubChem[3]), not the antigen-specific B cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Streptococcus pneumoniae type 9V capsular polysaccharide antigen-specific B cell.